Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Grows Stronger with Patents and Third-Party Partners

November 14, 2018 12:21:33
  • Improving the quality, taste and effectiveness of cannabis products with DehydraTECH
  • Recently granted two new U.S. patents, with over 50 additional patent applications filed worldwide
  • Applications span a wide range of products as the company out-licenses IP to third-party partners through a royalty model

Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) is using its DehydraTECH to increase the quality, taste and effectiveness of cannabis products. Lexaria’s revolutionary drug delivery platform is disrupting the way cannabidiol enters the bloodstream. Rather than relying on the traditional methods of inhalation, which has harmful lasting impact on a person’s health, DehydraTECH allows for a safer, more efficient means of ingestion. This edible technology increases the bioavailability of the drug, amplifying intestinal absorption by 5-10 times. It allows for a more controlled dosage, masks the bitter medicinal taste without the use of sugar and reduces the amount of time it takes to experience the desired effect.

DehydraTECH is patented for CBD and all other non-psychoactive cannabinoids, as well as for THC and psychoactive cannabinoids. The implications of these patents reach beyond cannabinoids, naming a broad range of lipophilic bioactives and food/carrier particles. The company recently announced that it has been granted two new U.S. patents related to certain cannabinoid-infused beverage compositions (http://nnw.fm/o6UZB). Currently, the company has over 50 patent applications filed worldwide.

Lexaria complements companies desiring to improve existing or create new products. The company can partner with the drug industry and enhance consumer products manufactured by partner companies. DehydraTECH is out-licensed to third-party partners through an affordable royalty model and is available in more than 40 countries where DehydraTECH is patented or patent-pending.

While Lexaria is currently focused on utilizing its technology in the medical and recreational cannabis, nicotine and NSAID industries, it has applications across a wide range of products. DehydraTECH has been used in processed foods, beverages, vitamins, pain relievers, smoking cessation and more.

John Docherty, president of Lexaria, shares an overview of how this technology and business model work in a short video found here: http://nnw.fm/Dez84.

For more information, visit the company’s website at www.LexariaBioscience.com

More from NetworkNewsWire

About NetworkNewsWire

NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with NNW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

To receive instant SMS alerts, text STOCKS to 77948

For more information, please visit https://www.NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

NetworkNewsWire (NNW)
New York, New York
212.418.1217 Office